Comparative study of oncologic outcomes for laparoscopic vs. open surgery in transverse colon cancer.
10.4174/astr.2014.86.1.28
- Author:
Woo Ram KIM
1
;
Se Jin BAEK
;
Chang Woo KIM
;
Hyun A JANG
;
Min Soo CHO
;
Sung Uk BAE
;
Hyuk HUR
;
Byung Soh MIN
;
Seung Hyuk BAIK
;
Kang Young LEE
;
Nam Kyu KIM
;
Seung Kuk SOHN
Author Information
1. Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. whitenoja@yuhs.ac
- Publication Type:Comparative Study ; Original Article
- Keywords:
Laparoscopic surgery;
Colonic neoplasm;
Colon;
Transverse
- MeSH:
Body Mass Index;
Colectomy;
Colon;
Colon, Transverse*;
Colonic Neoplasms;
Disease-Free Survival;
Humans;
Laparoscopy;
Length of Stay;
Operative Time;
Postoperative Complications;
Retrospective Studies;
Surgical Procedures, Operative
- From:Annals of Surgical Treatment and Research
2014;86(1):28-34
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Laparoscopic resection for transverse colon cancer is a technically challenging procedure that has been excluded from various large randomized controlled trials of which the long-term outcomes still need to be verified. The purpose of this study was to evaluate long-term oncologic outcomes for transverse colon cancer patients undergoing laparoscopic colectomy (LAC) or open colectomy (OC). METHODS: This retrospective review included patients with transverse colon cancer who received a colectomy between January 2006 and December 2010. Short-term and five-year oncologic outcomes were compared between these groups. RESULTS: A total of 131 patients were analyzed in the final study (LAC, 84 patients; OC, 47 patients). There were no significant differences in age, gender, body mass index, tumor location, operative procedure, or blood loss between groups, but the mean operative time in LAC was significantly longer (LAC, 246.8 minutes vs. OC, 213.8 minutes; P = 0.03). Hospital stay was much shorter for LAC than OC (9.1 days vs. 14.5 days, P < 0.01). Postoperative complication rates were not statistically different between the two groups. In terms of long-term oncologic data, the 5-year disease-free survival and overall survival were not statistically different between both groups, and subgroup analysis according to cancer stage also revealed no differences. CONCLUSION: LAC for transverse colon cancer is feasible and safe with comparable short- and long-term outcomes.
